SEARCH

SEARCH BY CITATION

References

  • 1
    Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 72733.
  • 2
    Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 8396.
  • 3
    Caldwell S, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 103946.
  • 4
    Shah U, Ma AD. Tests of platelet function. Curr Opin Hematol 2007; 14: 4327.
  • 5
    Ordinas A, Escolar G, Cirera I, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996; 24: 113742.
  • 6
    Michelson AD, Frelinger AL III, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98: 4N10N.
  • 7
    McKenzie ME, Gurbel PA, Levine DJ, Serebruany VL. Clinical utility of available methods for determining platelet function. Cardiology 1999; 92: 2407.
  • 8
    Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 105565.
  • 9
    Iannacone M, Sitia G, Isogawa M, et al. Platelets mediate cytotoxic t lymphocyte-induced liver damage. Nat Med 2005; 11: 11679.
  • 10
    Laschke MW, Dold S, Menger MD, Jeppsson B, Thorlacius H. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis. Br J Pharmacol 2008; 153: 14856.
  • 11
    Lesurtel M, Graf R, Aleil B, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 1047.
  • 12
    Aoki Y, Hirai K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 1993; 20: 1239.
  • 13
    Schmidt KG, Rasmussen JW, Bekker C, Madsen PE. Kinetics and in vivo distribution of 111-in-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol 1985; 34: 3946.
  • 14
    Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982; 99: 21730.
  • 15
    Toghill PJ, Green S. Splenic influences on the blood in chronic liver disease. Q J Med 1979; 48: 61325.
  • 16
    Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998; 79: 110610.
  • 17
    Panasiuk A, Prokopowicz D, Zak J, Panasiuk B. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration. Hepatogastroenterology 2004; 51: 11248.
  • 18
    Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795801.
  • 19
    Kajihara M, Okazaki Y, Kato S, et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22: 1128.
  • 20
    Wolber E, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002; 17: 610.
  • 21
    Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mrna expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89: 1017.
  • 22
    Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100: 13116.
    Direct Link:
  • 23
    Martin TG III, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127: 2858.
  • 24
    Sanjo A, Satoi J, Ohnishi A, Maruno J, Fukata M, Suzuki N. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 2003; 18: 63844.
  • 25
    Sezai S, Kamisaka K, Ikegami F, et al. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenterol 1998; 93: 802.
    Direct Link:
  • 26
    Koruk M, Onuk MD, Akçay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49: 16458.
  • 27
    Peck-Radosavljevic M, Zacherl J, Wichlas M, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gastroenterol Hepatol 1999; 11: 1516.
  • 28
    Aref S, Mabed M, Selim T, Goda T, Khafagy N. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 2004; 9: 3516.
  • 29
    Ghalib R, Levine C, Hassan M, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 116571.
  • 30
    Ichikawa N, Kitano K, Shimodaira S, et al. Changes in serum thrombopoietin levels after splenectomy. Acta Haematol 1998; 100: 13741.
  • 31
    Aster RH. Splenic platelet pooling as a cause of “hypersplenic” thrombocytopenia. Trans Assoc Am Physicians 1965; 78: 36273.
  • 32
    Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14(Suppl. D): 60D6D.
  • 33
    Männl HFK, Matzander U, Tkocz H, Buchwald W. Portal pressure, spleen size, hypersplenism and the problem of congestive splenomegaly in the surgery of portal hypertension in cirrhotics. Chir Gastroent (Gastroent. Surg.) 1975; 9: 5116.
  • 34
    Jabbour N, Zajko A, Orons P, Irish W, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (tips) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998; 43: 245962.
  • 35
    Karasu Z, Gurakar A, Kerwin B, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 2000; 45: 19716.
  • 36
    Gschwantler M, Vavrik J, Gebauer A, et al. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt – a prospective, controlled study. J Hepatol 1999; 30: 2549.
  • 37
    Jalan R, Redhead DN, Allan PL, Hayes PC. Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (tipss). Eur J Gastroenterol Hepatol 1996; 8: 3815.
  • 38
    Pursnani KG, Sillin LF, Kaplan DS. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 1997; 173: 16973.
  • 39
    Lawrence SP, Lezotte DC, Durham JD, Kumpe DA, Everson GT, Bilir BM. Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (tips). a retrospective analysis. Dig Dis Sci 1995; 40: 157580.
  • 40
    Mutchnick MG, Lerner E, Conn HO. Effect of portacaval anastomosis on hypersplenism. Dig Dis Sci 1980; 25: 92938.
  • 41
    Lee C, Leung T, Wang H, et al. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia. World J Gastroenterol 2007; 13: 61922.
  • 42
    Beer JH, Clerici N, Baillod P, Von Felten A, Schlappritzi E, Büchi L. Quantitative and qualitative analysis of platelet GPIb and von willebrand factor in liver cirrhosis. Thromb Haemost 1995; 73: 6019.
  • 43
    Kajihara M, Kato S, Okazaki Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 126776.
  • 44
    Kajiwara E, Akagi K, Azuma K, Onoyama K, Fujishima M. Evidence for an immunological pathogenesis of thrombocytopenia in chronic liver disease. Am J Gastroenterol 1995; 90: 9626.
  • 45
    Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995; 22: 16828.
  • 46
    Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995; 50: 1738.
  • 47
    Cioni G, Cristani A, Mussini C, et al. Incidence and clinical significance of elevated fibrin(ogen) degradation product and/or d-dimer levels in liver cirrhosis patients. Ital J Gastroenterol 1990; 22: 704.
  • 48
    Vardareli E, Saricam T, Demirustu C, Gulbas Z. Soluble p selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterology 2007; 54: 4669.
  • 49
    Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis p-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology 2001; 48: 81822.
  • 50
    Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77: 5137.
  • 51
    Schöffski P, Tacke F, Trautwein C, et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver 2002; 22: 11420.
  • 52
    Bassendine MF, Collins JD, Stephenson J, Saunders P, James OF. Platelet associated immunoglobulins in primary biliary cirrhosis: a cause of thrombocytopenia? Gut 1985; 26: 10749.
  • 53
    Panzer S, Penner E, Nelson PJ, Prochazka E, Benda H, Saurugger PN. Identification of the platelet glycoprotein IIb/IIIa complex as a target antigen in primary biliary cirrhosis-associated autoimmune thrombocytopenia. evidence that platelet-reactive autoantibodies can also bind to the mitochondrial antigen m2. J Autoimmun 1990; 3: 47383.
  • 54
    Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113: 5905.
  • 55
    Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 2000; 99: 20714.
  • 56
    Wang S, Tsai S, Chen G, Lan J, Yen T. In-111-labeled platelet scintigraphies in patients with chronic hepatitis C. Hepatogastroenterology 2002; 49: 10668.
  • 57
    Thomas DP, Ream VJ, Stuart PK. Platelet aggregation in patients with laennec’s cirrhosis of the liver. N Engl J Med 1967; 276: 13448.
  • 58
    Blake JC, Sprengers D, Grech P, McCormick PA, McIntyre N, Burroughs AK. Bleeding time in patients with hepatic cirrhosis. BMJ 1990; 301: 125.
  • 59
    Bonnard P, Vitte RL, Barbare JC, et al. Is bleeding time measurement useful for choosing the liver biopsy route? The results of a pragmatic, prospective multicentric study in 219 patients. J Clin Gastroenterol 1999; 29: 3479.
  • 60
    Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. group. coagulation abnormalities in cirrhosis study group. J Hepatol 1994; 20: 5316.
  • 61
    Escolar G, Cases A, Viñas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (pfa-100): influence of hematocrit elevation. Haematologica 1999; 84: 6149.
  • 62
    Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 5361.
  • 63
    Lisman T, Adelmeijer J, De Groot PG, Janssen HLA, Leebeek FWG. No evidence for an intrinsic platelet defect in patients with liver cirrhosis – studies under flow conditions. J Thromb Haemost 2006; 4: 20702.
  • 64
    Tonda R, Galán AM, Pino M, et al. Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. J Hepatol 2003; 39: 9549.
  • 65
    Ingeberg S, Jacobsen P, Fischer E, Bentsen KD. Platelet aggregation and release of atp in patients with hepatic cirrhosis. Scand J Gastroenterol 1985; 20: 2858.
  • 66
    Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi V, Gentilini P. Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis. FEBS Lett 1987; 220: 2179.
  • 67
    Laffi G, Cominelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988; 8: 16206.
  • 68
    Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology 1992; 103: 6416.
  • 69
    Laffi G, Marra F, Failli P, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology 1993; 105: 14856.
  • 70
    Laffi G, Cinotti S, Filimberti E, et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. J Hepatol 1996; 24: 43643.
  • 71
    Pantaleo P, Marra F, Vizzutti F, et al. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. Clin Sci (Lond) 2004; 106: 2734.
  • 72
    Rubin MH, Weston MJ, Langley PG, White Y, Williams R. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979; 24: 197202.
  • 73
    Willis SE, Jackson ML, Meric SM, Rousseaux CG. Whole blood platelet aggregation in dogs with liver disease. Am J Vet Res 1989; 50: 18937.
  • 74
    Younger HM, Hadoke PW, Dillon JF, Hayes PC. Platelet function in cirrhosis and the role of humoral factors. Eur J Gastroenterol Hepatol 1997; 9: 98992.
  • 75
    Albornoz L, Bandi JC, Otaso JC, Laudanno O, Mastai R. Prolonged bleeding time in experimental cirrhosis: role of nitric oxide. J Hepatol 1999; 30: 45660.
  • 76
    Sánchez-Roig MJ, Rivera J, Moraleda JM, García VV. Quantitative defect of glycoprotein Ib in severe cirrhotic patients. Am J Hematol 1994; 45: 105.
  • 77
    Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43: 26771.
  • 78
    Papatheodoridis GV, Patch D, Webster GJ, Brooker J, Barnes E, Burroughs AK. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 1999; 29: 108590.
  • 79
    Davì G, Migneco G, Vigneri S, Tripi S, Scialabba A, Strano A. Platelet thromboxane production in liver cirrhosis. Prostaglandins Leukot Med 1985; 19: 99104.
  • 80
    Luzzatto G, Fabris F, Gerunda GE, Zangrandi F, Girolami A. Failure of two anti-platelet drugs (indobufen and dipyridamole) to improve thrombocytopenia in liver cirrhosis. Acta Haematol 1987; 77: 1016.
  • 81
    Chamone DA, Van Hoof A, Vermylen J. Increased release of prostacyclin-like activity from rat aorta by plasma from patients with hepatic or renal failure. Arq Gastroenterol 1987; 24: 169.
  • 82
    Kunihiro N, Kawai B, Sanjo A, Osaka K, Ohnishi A. Platelet aggregation and coagulation and fibrinolysis parameters in both portal and systemic circulations in patients with cirrhosis and hepatocellular carcinoma. Hepatol Res 2001; 19: 529.
  • 83
    Laffi G, La Villa G, Pinzani M, et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 1986; 90: 27482.
  • 84
    Laffi G, Foschi M, Masini E, et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 1995; 22: 166673.
  • 85
    Desai K, Mistry P, Bagget C, Burroughs AK, Bellamy MF, Owen JS. Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989; 1: 6935.
  • 86
    Fuse I. Disorders of platelet function. Crit Rev Oncol Hematol 1996; 22: 125.
  • 87
    Solum NO, Rigollot C, Budzyński AZ, Marder VJ. A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. Br J Haematol 1973; 24: 41934.
  • 88
    Baele G, Beke R, Barbier F. In vitro inhibition of platelet aggregation by bile salts. Thromb Haemost 1980; 44: 624.
  • 89
    Pereira J, Accatino L, Pizarro M, Mezzano V, Ibañez A, Mezzano D. In vivo effect of bile salts on platelet aggregation in rats. Thromb Res 1995; 80: 35762.
  • 90
    Lisman T, Leebeek FWG, De Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37: 2807.
  • 91
    Moiny G, Thirion A, Deby C. Bilirubin induces platelet aggregation. Thromb Res 1990; 59: 4136.
  • 92
    Baele G, Rasquin K, Barbier F. Coagulant, fibrinolytic, and aggregating activity in ascitic fluid. Am J Gastroenterol 1986; 81: 4403.
  • 93
    Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989; 96: 15529.
  • 94
    Biagini MR, Guadascione M, McCormick AP, Raskino C, McIntyre N, Burroughs AK. Bleeding varices in PBC and its prognostic significance. Gut 1990; 31: A1209.
  • 95
    Palareti G, Legnani C, Maccaferri M, et al. Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient’s disease and use of antithrombin III concentrates. S. orsola working group on liver transplantation. Haemostasis 1991; 21: 6876.
  • 96
    Shannon P, Wanless IR. The site of vascular obstruction in early stage primary biliary cirrhosis with portal vein (pv) thrombosis. Hepatology 1995; 22: 253A.
  • 97
    Ben-Ari Z, Panagou M, Patch D, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol 1997; 26: 5549.
  • 98
    Pihusch R, Rank A, Göhring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37: 54855.
  • 99
    Biagini MR, Tozzi A, Marcucci R, et al. Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. World J Gastroenterol 2006; 12: 160712.
  • 100
    Atucha NM, Iyú D, Alcaraz A, et al. Altered calcium signalling in platelets from bile-duct-ligated rats. Clin Sci (Lond) 2007; 112: 16774.
  • 101
    Rubin R. Effects of ethanol on platelets. Lab Invest 1999; 63: 72932.
  • 102
    Torres Duarte AP, Dong QS, Young J, Abi-Younes S, Myers AK. Inhibition of platelet aggregation in whole blood by alcohol. Thromb Res 1995; 78: 10715.
  • 103
    Barrison IG, Viola L, Murray-Lyon IM. Platelet prostaglandin production in alcoholic liver disease. Prostaglandins Leukot Med 1983; 10: 33144.
  • 104
    Hillbom M, Muuronen A, Neiman J. Liver disease and platelet function in alcoholics. Br Med J (Clin Res Ed) 1987; 295: 581.
  • 105
    Hillbom M, Neiman J. Platelet thromboxane formation capacity after ethanol withdrawal in chronic alcoholics. Haemostasis 1988; 18: 1708.
  • 106
    Watanabe M, Shiraishi K, Itakura M, Matsuzaki S. Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease. Alcohol Clin Exp Res 1998; 22: 97S102S.
  • 107
    Ouwendijk RJ, Zijlstra FJ, Wilson JH, Bonta IL, Vincent JE. Raised plasma thromboxane B2 levels in alcoholic liver disease. Prostaglandins Leukot Med 1983; 10: 11522.
  • 108
    Ferroni P, Mammarella A, Martini F, et al. Increased soluble p-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. J Investig Med 2001; 49: 40712.
  • 109
    Bajaj JS, Bhattacharjee J, Sarin SK. Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis. J Gastroenterol Hepatol 2001; 16: 6416.
  • 110
    Prasad CV, Kaur U, Marwaha N, Ghosh K, Chawla YK, Dilawári JB. Hemostatic alterations in non-cirrhotic portal fibrosis, extrahepatic portal venous obstruction and budd-chiari syndrome. Indian J Gastroenterol 1990; 9: 5760.
  • 111
    Eizayaga FX, Aguejouf O, Belon P, Doutremepuich C. Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin. Pathophysiol Haemost Thromb 2005; 34: 2934.
  • 112
    Dayal S, Pati HP, Pande GK, Sharma P, Saraya AK. Platelet ultra-structure study in budd-chiari syndrome. Eur J Haematol 1995; 55: 294301.